Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
  • Company Profiles
  • Target Profiles
  • Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 12, 2022
Product Development

CRISPR Therapeutics advances CAR T modality in T cell cancers

CRISPR-edited CAR T CTX130 generates responses in challenging T cell lymphoma indications
BioCentury | Feb 16, 2022
Product Development

Legend clinical hold raises questions about CAR Ts for T cell cancers

A drop in CD4+ T cells triggers clinical hold for Legend CAR T trial
BioCentury | Jun 15, 2018
Financial News

Autolus proposes IPO terms

BioCentury | Jun 8, 2018
Financial News

Autolus proposes IPO terms

BioCentury | Nov 14, 2017
Distillery Therapeutics

Cancer

BioCentury | Sep 29, 2017
Finance

Fueling up

How Autolus’ $80M series C round sets company up to advance CAR T pipeline
Items per page:
1 - 7 of 7